Longevity Medicine
What Is Prostate Cancer Screening?
Last reviewed: May 2026 · Haute MD Editorial Team
Prostate cancer screening uses the PSA (prostate-specific antigen) blood test as the primary tool, increasingly combined with prostate MRI and genomic risk stratification. The goal of modern screening is to detect aggressive cancers early while minimizing overdiagnosis and overtreatment of indolent disease — a problem that historically caused PSA screening to fall out of favor.
How modern prostate screening works
Standard screening begins with PSA blood testing — typically starting at age 50 for average-risk men, or 40-45 for higher-risk men (Black men, first-degree relative with prostate cancer, BRCA carriers). Rather than treating any elevation as immediate biopsy indication, modern practice uses age-adjusted thresholds, PSA velocity (rate of change), PSA density (PSA normalized to prostate volume), free-to-total PSA ratio, and additional biomarkers (4Kscore, PHI, MyProstateScore). Elevated or rising PSA typically prompts multiparametric prostate MRI rather than immediate biopsy — MRI can identify clinically significant lesions and avoid biopsy in many men with negative scans. When biopsy is indicated, MRI-fusion targeted biopsy improves detection of significant cancer compared to systematic biopsy alone.
Why screening recommendations have evolved
Early PSA screening reduced prostate cancer mortality but at the cost of significant overdiagnosis — many indolent cancers that would never have caused harm were detected and treated, with associated incontinence and erectile dysfunction from radical treatment. This led to USPSTF downgrading PSA screening in 2012. Subsequent evidence and improved workup pathways have restored a more nuanced position: shared decision-making at 55-69 (USPSTF), with strong consideration starting at 45-50 in higher-risk men. Active surveillance for low-risk disease (~50% of newly diagnosed cancers in the U.S. are now managed without immediate treatment) has dramatically reduced overtreatment. The result is a screening landscape that catches aggressive disease while leaving indolent disease alone.
How to approach screening as a patient
(1) Discuss baseline PSA with your physician starting at 45 (40 if Black or family history or known BRCA carrier); (2) Track PSA trends — rate of rise often matters more than a single value; (3) Don't accept biopsy reflexively for elevated PSA — request prostate MRI first in most cases; (4) Understand Gleason grading — Grade Group 1 (Gleason 6) cancers are typically managed by active surveillance, not surgery or radiation; (5) Consider germline genetic testing if family history or high-grade disease — BRCA1/2 and other mutations alter both screening intensity and treatment options; (6) Continue screening through age 70-75 in healthy men; less benefit beyond that. Modern prostate screening is one of the better examples of how careful risk stratification has transformed a once-controversial intervention into a high-yield component of male longevity care.
Frequently Asked Questions
When should I start PSA screening?
Age 50 for average-risk men, 45 for Black men and those with first-degree family history, and 40 for BRCA1/2 carriers or men with multiple affected relatives. Continue through age 70-75 if generally healthy.
Should I get a prostate MRI before biopsy?
In most cases, yes. Multiparametric prostate MRI before biopsy is now standard in many guidelines — it can identify clinically significant lesions, avoid biopsy in many men with negative scans, and guide targeted biopsy when needed.
What does a Gleason 6 (Grade Group 1) result mean?
Low-grade prostate cancer that rarely metastasizes. Most men with Grade Group 1 disease are managed by active surveillance — regular PSA, MRI, and periodic biopsy — rather than immediate surgery or radiation. Many never require treatment.
Does PSA screening cause overdiagnosis?
Historically yes, when every elevation led to biopsy and every cancer to treatment. Modern pathways using MRI before biopsy and active surveillance for low-grade disease have substantially reduced this. The net benefit-harm balance is now considered favorable in properly selected, properly managed men.
Get Help Now
Speak with a Haute MD Longevity Medicine physician
Dr. George Kaltner
CEO
Longevity Medicine · Miami Beach, FL
View Profile
Dr. Alexander Golberg
Longevity Medicine · New York, NY
View Profile
Dr. Steven Victor
Regenerative Medicine Specialist
Longevity Medicine · New York, NY
View ProfileAre you a Longevity Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · LONGEVITY MEDICINE
What Is Preventive Oncology?
Preventive oncology applies risk stratification, advanced screening, and lifestyle interventions to detect cancer earlier and reduce lifetime cancer risk.
Read GuideGuide · LONGEVITY MEDICINE
What Is Genetic Cancer Risk Testing?
Germline genetic testing identifies inherited cancer risk mutations like BRCA, Lynch, and others — enabling personalized prevention and screening.
Read GuideGuide · LONGEVITY MEDICINE
What Is Liquid Biopsy?
Liquid biopsy is a blood test that detects circulating tumor DNA and other cancer-derived material to enable earlier detection and monitoring.
Read Guide